Quote | BioLineRx Ltd. (NASDAQ:BLRX)
|Last Trade Date Time:||12/04/2023 03:00:00 am|
News | BioLineRx Ltd. (NASDAQ:BLRX)
2023-12-04 18:42:54 ET Summary BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Fina...
2023-12-02 23:25:30 ET Summary BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for ...
Message Board Posts | BioLineRx Ltd. (NASDAQ:BLRX)
|BioLineRx to Report First Quarter 2023 Results on||midastouch017||investorshub||05/17/2023 12:03:40 PM|
|Philip Serlin: I would like to take a||midastouch017||investorshub||05/11/2023 5:17:14 PM|
|1.6792+0.1692 (+11.2053%)||midastouch017||investorshub||05/11/2023 3:10:39 PM|
|Lets go go go go... Up up and away we go.||midastouch017||investorshub||05/11/2023 2:03:17 PM|
|Three out of four: Protlix also received marketing||midastouch017||investorshub||05/11/2023 12:48:56 PM|
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Auto...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
BioLineRx Ltd. (BLRX) is expected to report $-0.18 for Q3 2023